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ABSTRACT
This study describes the first phase II study of S-1, a
novel oral fluoropyrimidine, in a non-Japanese Asian
population with advanced gastric cancer. S-1 was ad-
ministered twice daily for 28 days every 6 weeks. A
pharmacokinetic study was performed on day 28 of cy-
cles 1 and 3. Genomic DNA from peripheral mononu-
clear cells was analyzed using a cDNA microarray-
based comparative genomic hybridization (CGH)
method. Thirty-one patients were initially given a dose
of 35 mg/m2 twice daily (bid) (group 1); then, the proto-
col was amended by increasing the dose to 40 mg/m2 bid
for an additional 31 patients (group 2) because of good
tolerability to S-1. The overall response rate was 19.3%
(95% confidence interval, 9.2%–29.5%). Over a median
follow-up duration of 265 days, the median time to pro-
gression and overall survival time were 126 and 264
days, respectively. The 1-year survival rate was 34%.
There was no grade 4 toxicity and the major adverse event
was anemia. Pharmacokinetic parameters were similar to
those of the previous Japanese reports. Microarray CGH
identified 18 genes with copy number changes that were
associated with hemoglobin reduction with S-1 treatment.
A logistic regression analysis, integrating one clinical pa-
rameter (initial hemoglobin level) combined with three ge-
netic copy number variations (HIST1H2BL, C10orf127,
and XPNPEP2), provided a predictive model for the devel-
opment of severe hemoglobin reduction. In conclusion,
this study showed the feasibility of using S-1 at 35 mg/m2
bid in gastric cancer. We suggest that the pharmaco-
genomic markers identified in this study may be potential
candidates for predicting anemia after S-1 treatment. The
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INTRODUCTION
Systemic chemotherapy is tried in advanced gastric cancer
in order to improve patient survival and quality of life
[1–3]. 5-Fluorouracil (5-FU) has served as a mainstay of
chemotherapy in this setting. Bolus injection of 5-FU
showed a 13%–20% response rate while its protracted con-
tinuous infusion (PCI) showed an 18%–26% response rate
[4–8]. Although few full-scale trials have been conducted
to directly compare these two schedules of 5-FU, PCI is re-
garded as an acceptable reference treatment in gastric can-
cer, with less myelosuppression and diarrhea.
S-1 is a fourth-generation oral fluoropyrimidine that
was developed to mimic PCI of 5-FU. A high 5-FU level
was maintained both in plasma and in tumor without in-
creasing gastrointestinal toxicity by combining tegafur
(FT) with two biochemical modulators, 5-chloro-2,4-dihy-
droxypyridine (CDHP) and potassium oxonate (Oxo) [9,
10]. With S-1 monotherapy, early and late phase II trials in
Japan achieved promising efficacy rates of 54% and 45%,
respectively [11–14]. However, the dose administered was
not the same between these studies. Derived from the result
of a phase I study, the early phase II study adopted a fixed
dose of 75 mg twice a day (bid). However, skin rash and
diarrhea hindered further progress of the study with this
dose, and the dose had to be reduced to 50 mg bid. After
reconsideration of the safety profile of S-1, the dose for the
late phase II study was modified, ranging from 64 mg/m2
per day to 80 mg/m2 per day according to body surface area
(BSA)—80 mg for BSA1.25 m2, 100 mg for BSA 1.25–
1.50 m2, 120 mg for BSA1.50 m2. The safety profile was
better, and based on this dosage S-1 has been a preferred
oral agent in gastric cancer in Japan [15]. However, such a
high initial tumor response for S-1 has not been reproduced
beyond Japan [16, 17]. A phase I U.S. trial had to restrict the
clinically recommended dose to 60 mg/m2 a day because of
dose-limiting toxicities (DLTs) of diarrhea and hyperbiliru-
binemia; and in one European phase II trial as well, diarrhea
caused immediate dose reduction of the initial daily dose of
80 mg/m2 after a few patients were enrolled [16, 18]. These
findings suggest that some kind of ethnic differences may
contribute to treatment outcome with S-1.
The present study describes a phase II trial of S-1 mono-
therapy that is the first conducted in a non-Japanese Asian
population. The primary objectives were to determine the
efficacy and safety of S-1 in previously untreated advanced
gastric cancer. As part of the secondary objectives, we also
performed a pharmacokinetic study and pharmacogenomic
evaluations using cDNA microarray-based comparative
genomic hybridization (CGH) to find adverse event–related
biomarkers.
MATERIALS AND METHODS
Patient Selection
This study was designed as an open-labeled multi-institu-
tional phase II trial. Patients were required to have: histo-
logically confirmed gastric adenocarcinoma with
inoperable or metastatic disease; age 18 years; a perfor-
mance status score 2 according to the Eastern Coopera-
tive Oncology Group criteria; a life expectancy of 3
months; no prior chemotherapy for advanced disease (ad-
juvant chemotherapy had to have been completed at least 6
months before enrollment); bidimensionally measurable le-
sions; and adequate organ function (WBC 4,000/l, he-
moglobin (Hb)  9.0 g/dl, platelets 100,000/l, serum
creatinine 1.5 upper limit of normal (ULN), total bili-
rubin 1.25 ULN, and serum aminotransferase 2.5
ULN). Patients must not have had other active malignan-
cies, brain metastasis, or severe comorbid conditions. After
the protocol was approved by the institutional review board
(IRB), written informed consent with ICH Guidelines was
obtained from patients according to each institution’s reg-
ulations.
Treatment Protocol
The initially planned dose of S-1 for this trial was 35 mg/m2
bid (Table 1). The patients were assigned to take S-1 ac-
cording to BSA, which was rounded off, as in Table 1. S-1
was administered within 1 hour after meals (breakfast and
supper) for 28 consecutive days, followed by a 2-week rest.
The schedule was repeated until the occurrence of disease
progression, unacceptable adverse events, or the patient’s
withdrawal. If grade 3 adverse events were shown in the
previous course, the dose for the next cycle was reduced by
5 mg/m2, which corresponds to 30 mg/m2 bid. Patients who
required 4 weeks of rest for recovery from any toxicity
other than alopecia, nausea, vomiting, and anemia, or who
required a dose reduction of more than two steps (i.e., 10
mg/m2, corresponding to 25 mg/m2 bid), were withdrawn
from the study.
Evaluation of Patients
Pretreatment evaluations included a complete medical his-
tory, performance status assessment, physical and radiolog-
ical examinations, electrocardiography, and clinical
laboratory tests including CBC, serum biochemistry, and
urinalysis. During treatment, patients were evaluated with a
weekly CBC. The physical examination, performance sta-
tus evaluation, imaging studies for tumor measurement, and
serum biochemistry tests were re-evaluated prior to each
cycle. Imaging studies for tumor response were performed
after each cycle. Tumor response was measured bidimen-
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sionally according to the World Health Organization crite-
ria. Patients were considered as evaluable for response if
they had received a minimum of one cycle of treatment with
at least one follow-up tumor measurement. Primary gastric
mass, peritoneal thickening, or ascites were considered
nonmeasurable, and follow-up gastroduodenoscopy was
planned for patients with a complete response (CR). Ad-
verse events were recorded every week and graded accord-
ing to the National Cancer Institute Common Toxicity
Criteria (Version 2.0).
Statistical Consideration of the Phase II Trial
With reference to the previous results for PCI of 5-FU, S-1
was considered active if the response rate exceeded 20%.
The hypothesis was: H0, p  p0 (0.10) versus H1, p  p1
(0.20), with  0.05 and  0.10 (90% power). Accord-
ing to Simon’s optimal design and considering a 10% drop-
out rate, 49 patients who met the criteria for response
evaluation were required [19].
However, after the first 31 patients were enrolled, inves-
tigators decided to escalate the dose of S-1 because most of
the patients tolerated S-1 well and showed favorable com-
pliance. After protocol amendment and IRB reapproval, the
study proceeded with this dose increase in another 31 pa-
tients. Thus, the initially enrolled 31 patients (group 1) con-
tinued the study with dosage based on 35 mg/m2 bid, while
the 31 newly enrolled patients were treated with an S-1 dos-
age based on 40 mg/m2 bid (group 2), resulting in 62 pa-
tients enrolled overall (Table 1). The dose-modification
strategy and schedule for group 2 were the same as for
group 1, except for the lowest permitted dosage (25 mg/m2
bid for group 1 and 30 mg/m2 bid for group 2). The data
were analyzed according to all enrolled patients and for
each dose group as well. Statistical analysis was done using
the SPSS program (version 12.0, SPSS, Inc., Chicago, IL).
Time-dependent variables were estimated using the
Kaplan-Meier method.
Pharmacokinetic Study
A pharmacokinetic study was performed in the first and
third cycles for three patients in each dosing group. On day
28, peripheral blood was collected before and 1, 2, 3, 6, 8,
10, 14, 24, and 48 hours after the final administration of S-1.
Plasma was isolated and stored at 80°C. Urine samples
were collected 12 hours before the last dose of S-1 and for
the periods of 0–6, 6–12, 12–18, and 18–24 hours after S-1
treatment. After estimation of the total urine volumes,
10-ml samples were stored at80°C until analysis.
Analyses of FT, 5-FU, CDHP, and Oxo were conducted
according to the method described by Matsushima et al.
[20, 21]. Briefly, FT was extracted with dichloromethane
from each sample and analyzed using HPLC equipped with
a UV absorption spectrophotometer. 5-FU and CDHP were
extracted with ethyl acetate, and Oxo was separately ex-
tracted using a solid extraction column. They were ana-
lyzed using a negative ion chemical ionization-gas
chromatography mass spectrophotometer. The lower mea-
surable limit of plasma levels for FT, 5-FU, CDHP, and
Oxo were 10, 1, 2, and 1 ng/ml, respectively.
cDNA-based Microarray CGH
We used 17K cDNA microarray containing 15,723 unique
genes for the cDNA-based microarray CGH. The whole ex-
periment was performed according to the protocol of the
Cancer Metastasis Research Center, Yonsei University
College of Medicine, Korea, in a sex-matched design [22,
23]. Briefly, 8 g of genomic DNA isolated from patients’
peripheral mononuclear cells was labeled with Cy3- or
Cy5–2-deoxyuridine 5-triphosphate, using a Bioprime la-
beling kit (Invitrogen, Carlsbad, CA). The labeled probes
Table 1. Dose schedule of S-1 according to body surface area (BSA)
Dosage schedule
Group 1
35 mg/m2
Group 2
40 mg/m2 Japanese
BSA
(m2)
Calculated dose
(mg)
Actual dose
(mg)
Calculated dose
(mg)
Actual dose
(mg) BSA (m2)
Actual dose
(mg)
1.36 47.6 45 54.4 50 1.25 40
1.36–1.57 47.6–55.0 50 54.4–62.8 60 1.25–1.50 50
1.58–1.78 55.3–62.3 60 63.2–72 70 1.50 60
1.79–1.92 62.6–67.2 65 71.6–76.8 75
1.93–2.07 67.5–72.4 70 77.2–82.8 80
2.08 72.8 75 83.2 80
The patients were assigned to take S-1 twice a day for 28 consecutive days followed by a 2-week rest. The Japanese dose
schedule is from Sakata et al. [14].
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were then mixed with human Cot-1 DNA (GIBCO-BRL,
Gaithersburg, MD), yeast tRNA (GIBCO-BRL), and
poly-A RNA (Sigma, St. Louis, MO). After concentration
and denaturation, the probe mixture was applied to the mi-
croarray and hybridized in a hybridization chamber at 65°C
for 16 hours.
After hybridization, slides were scanned using a Gene-
Pix 4000B scanner (Axon Instruments, Foster City, CA)
and TIFF images were analyzed. The signal intensity of
each spot was transformed as the log2 red to green (R/G)
ratio. Whole microarray spots were mapped for their chro-
mosomal location, using the software SOURCE (http://
genome-www5.stanford.edu/cgi-bin/source/sourceSearch)
and DAVID (http://apps1.niaid.nih.gov/david/). Within-
slide global normalization was applied, which subtracted
the median intensity ratio of the log2(R/G) from the log2-
transformed data.
Pharmacogenomic Study of S-1–Associated
Anemia
Patients were categorized according to the degree of hemo-
globin (Hb) reduction per treatment cycle into two groups:
the mild reduction group (MRG) and the severe reduction
group (SRG). To identify genetic changes that could dis-
criminate between the two groups, we selected genes show-
ing: (a) copy number variations, defined as an amplification
(log2(R/G)0.68) or a deletion (log2(R/G)0.68); and
(b) a frequency difference 30% between the MRG and
SRG [24]. Using the binary outcomes of the MRG and SRG
as the dependent variable, a best logistic regression model
was identified by performing stepwise selection. The diag-
nostic accuracy of this model with regard to the severity of
Hb reduction was quantified via prediction accuracy and re-
ceiver operating characteristic (ROC) analysis.
RESULTS
Patient Characteristics
From September 2003 to November 2004, a total of 62 pa-
tients was enrolled. Fifty-seven patients were evaluable for
response. Four patients withdrew their consent after the
first cycle of treatment, and one patient stopped treatment
as a result of rapid symptomatic deterioration during the
first cycle of treatment.
The median BSA of all patients was 1.67 m2 (range,
1.27–2.09). Thirteen patients received prior adjuvant che-
motherapy after curative gastrectomy. Liver and abdominal
lymph nodes were common sites for measurable lesions,
and a primary gastric mass was the main nonmeasurable le-
sion. The average size of the measurable lesions was 1,200
mm2 (range, 115–2,392), and the median number of mea-
surable lesions per patient was two (range, 1–5). Baseline
characteristics of these patients are presented in Table 2.
Treatment Outcomes
A total of 163 cycles (82 in group 1; 81 in group 2) was ad-
ministered, with a median number of cycles of two (range,
1–10). The median dose administered was 120 mg in group
1 (range, 90–150) and 140 mg in group 2 (range, 100–150).
The planned dose intensity was 327 mg/m2 per week in
group 1 and 373 mg/m2 per week in group 2. In group 1,
only two patients were subjected to a dose reduction be-
cause of an adverse event, resulting in a median actual dose
intensity (ADI) of 327 mg/m2 per week (relative dose in-
tensity [RDI], 1.00) (range, 236–327). In group 2, dose re-
duction occurred in seven patients, and the median ADI was
367 mg/m2 per week (RDI, 0.98; range, 189 –373). The
overall median dose intensity was 327 mg/m2 per week, and
no treatment delay was recorded in either group.
If we analyzed dose intensity according to the daily dose
administered, there was no significant difference in the me-
dian RDI for each dose level (100 mg, 0.97; 120 mg, 0.99;
130 mg, 1.0; 140 mg, 1.0; 150 mg, 0.92). This suggests that
S-1 showed favorable compliance throughout all dose lev-
els.
Efficacy
The confirmed overall response rate was 19.3% by intent-
to-treat analysis (95% confidence interval [CI],
9.2%–29.5%). All the responses were partial responses
(PRs), without a CR (Table 3). The median time to response
was 35 days (range, 35–245), and the median response du-
ration was 153 days (range, 68–559). One patient from
group 1 who had a CR of all measurable lesions and stable
disease (SD) of a gastric mass underwent curative surgery
after four cycles.
There were 13 cases of unconfirmed PRs; initial re-
sponses in nine patients were not confirmed at the next cy-
cle, and the remaining four patients failed to proceed to the
next cycle, because of symptomatic deterioration, early
death, gastrorrhagia, or patient refusal. Abdominal lymph
nodes showed a higher response than liver or other lesions
(48% versus 32% or 33%). There were no significant dif-
ferences in response with respect to initial size or number of
lesions.
Survival
Over a median follow-up of 265 days (group 1, 270 days;
group 2, 264 days), 57 patients showed disease progression,
and 50 patients (81%) died. The median time to progression
for all patients was 126 days (95% CI, 77–175) (Fig. 1A)—
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141 days (95% CI, 88–194) for group 1 and 119 days (95%
CI, 65–173) for group 2 (Fig. 1B).
The median overall survival duration for all patients was
264 days (95% CI, 233–295)—270 days (95% CI, 154 –
386) for group 1 and 264 days (95% CI, 212–316) for group
2 (Fig. 1C). The overall 1-year survival rate was 34%.
Adverse Events
There was no grade 4 adverse event documented in any of
the patients. The incidence of adverse events increased with
the increased dose. Although the toxicity profiles were not
different between the two dosing groups, the incidence of
hyperbilirubinemia was exclusively high in group 2 (Table
4). We experienced a sudden mortality in group 2 after the
first cycle of treatment, without evidence of disease pro-
gression or any specific event. The most common severe
(grade3) hematologic adverse event was anemia without
evidence of bleeding, which was documented in eight pa-
tients (13%). Three patients received transfusions because
of symptomatic anemia. The major nonhematologic ad-
verse event was colicky abdominal pain during treatment,
and severe (grade 3) diarrhea was recorded in only two
patients (3%).
Pharmacokinetics
Pharmacokinetic samples were collected from three pa-
tients in each dose level on day 28 of the first and the third
cycles. Pharmacokinetic parameters of FT, 5-FU, CDHP,
and Oxo at the different dose levels are summarized in Ta-
ble 5. Plasma levels of FT steadily increased after the ad-
ministration of S-1. Mean values for the maximum plasma
concentration and area under the plasma concentration-
Table 2. Patient characteristics
Characteristic
Group 1
35 mg/m2
Group 2
40 mg/m2 Total
n of enrolled patients 31 31 62
n of evaluable patients 28 29 57
Age in years (median) 28–75 (61) 23–71 (54) 23–75 (57)
Sex (M:F) 27:4 21:10 48:14
Performance status score
0–1 29 31 60
2 2 0 2
Prior treatment
None 20 22 42
Gastrectomy only 4 3 7
Gastrectomy plus adjuvant therapy 7 6 13
Histology
Well differentiated 1 1 2
Moderately differentiated 12 12 24
Poorly differentiated 14 11 25
Signet ring cell 2 6 8
Undifferentiated 2 1 3
Number of involved organs
One 10 21 31
Two 14 8 22
Three 4 2 6
Four or more 3 – 3
Number of target lesions per patient
One 11 5 16
Two 8 12 20
Three 7 10 17
Four or more 5 4 9
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versus-time curve from time 0 to 48 hours (AUC0–48) for
5-FU, CDHP, and Oxo accordingly increased with the dose
increase.
Mean AUC0–48 values for 5-FU and CDHP were higher
in cycle 3 than in cycle 1, while other parameters showed
little changes because of the 2-week washout period. This
increase for 5-FU and CDHP might imply a correlation be-
tween dihydropyrimidine dehydrogenase inhibition by
CDHP and 5-FU level after S-1 administration.
Pharmacogenomic Evaluation
We investigated pharmacogenomic classifiers associated
with Hb reduction after S-1 treatment in 36 patients. The
median values of Hb before treatment and nadir during
treatment were 11.3 g/dl (range, 9.2–15.3) and 9.4 g/dl
(range, 7.0 –13.2), respectively. The mean Hb reduction
rate per cycle was 1.0 (range, 0.0 –3.1), which was the
boundary value for separating the patients into the MRG
(Hb/cycle 1.0) and SRG (Hb/cycle 1.0). Twenty-
two patients were categorized into the MRG, and the re-
maining 14 patients were categorized into the SRG. There
were no statistical differences with regard to median age
(p .83), sex (p .43), performance status score (p .66),
or dose intensity (p .72) between these two groups.
Using microarray CGH, 18 genes with copy number
changes (12 amplified, 6 deleted) were identified that dis-
criminated between the MRG and SRG (Fig. 2A; online
supplementary Table 1). By univariate analysis, the clinical
factor initial Hb level and the copy number variation in
eight genes (HIST1H2BL, CLN6, C10orf127, SPATS2,
CA11, XPNPEP2, DJ167A19.1, and LOC158257) were
each significantly correlated with Hb reduction. A logistic
Table 3. Treatment response
Group 1
35 mg/m2
Group 2
40 mg/m2 Total
n of enrolled patients 31 31 62
n of evaluable patients 28 29 57
n ITT (%) PP (%) n ITT (%) PP (%) n ITT (%) PP (%)
CR – – – – – – – – –
PR (confirmed) 5 16.1 17.9 7 22.6 24.1 12 19.3 21.0
PR (unconfirmed) 5 16.1 17.9 7 22.6 24.1 12 19.3 21.0
SD 11 35.5 39.3 11 35.5 37.9 22 35.5 38.6
PD 7 22.6 25.0 4 12.9 13.8 11 17.7 19.3
Response rate (initial) 32.2 35.8 45.2 48.3 38.6 42.0
Response rate (confirmed) 16.1 17.9 22.6 24.1 19.3 21.1
(95% CI) (2.4–29.8) (7.0–38.2) (9.2–29.5)
Disease control rate 67.7 75.0 80.6 86.2 74.2 80.7
Abbreviations: CI, confidence interval; CR, complete response; ITT, intent-to-treat analysis; PD, progressive disease; PP,
per protocol analysis; PR, partial response; SD, stable disease.
Figure 1. (A): Progression-free survival and overall survival curves of all patients with a median follow-up duration of 265 days.
(B): Progression-free survival. (C): Overall survival curves of the patients according to dosing group. The median follow-up
duration was 270 days for group 1 (35 mg/m2 twice daily) and 264 days for group 2 (40 mg/m2 twice daily).
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regression model was built, and the combination of the fol-
lowing components provided the best logistic model in pre-
dicting Hb reduction: initial Hb level (p  .03), log2(R/G)
ratio of HIST1H2BL (p  .05), C10orf127 (p  .02), and
XPNPEP2 (p .05). The best logistic regression (Z) was as
follows: logit LN(Z)  18.767  (1.658  initial Hb
level)  (10.466  HIST1H2BL)  (10.57 
C10orf127) (8.67 XPNPEP2). The final model pre-
dicted correctly for 33 of 36 patients (92%) and misclassi-
fied one patient from the MRG and two patients from the
SRG. The AUC was 0.98 for the final regression model
(Fig. 2B).
DISCUSSION
Upon designing this phase II study, our first speculation
was the dosage of S-1. Japanese trials have adopted a dos-
ing system based on 80 mg/m2 with a schedule of 6 weeks
per cycle that roughly follows BSA, limiting the maximal
dosage to 120 mg in patients with a BSA1.50 m2 [13–15,
25–28]. This may result in an inadvertent underdosage in
patients with a high BSA. On the other hand, western trials
followed a BSA-based scheme with a schedule of 5 weeks
per cycle. However, in one European phase II trial, a daily
dose of 80 mg/m2 was intolerable, with the occurrence of
severe nonhematological toxicity [16]. Therefore, in order
to procure an adequate dose intensity without impeding
safety, we started the initial dosage at 35 mg/m2 adjusted by
BSA with a schedule of 6 weeks per cycle. The resulting
planned dose intensity was 327 mg/m2 per week, and eight
patients (26%) were assigned to an S-1 dosage that was
higher than the dosage from the conventional Japanese trial
—seven patients at 130 mg, one patient at 150 mg.
Table 4. Adverse events
Adverse event
Group 1
35 mg/m2 (n 31)
Group 2
40 mg/m2 (n 31) Total (n 62)
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)a
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)a
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)a
Anemia 13 (41.9) 11 (35.4) 3 (9.7) 8 (26.8) 13 (41.9) 5 (16.1) 21 (33.9) 24 (38.7) 8 (12.9)
Leukopenia 5 (16.1) 1 (3.2) 1 (3.2) 12 (38.7) 2 (6.5) – 17 (27.4) 3 (4.8) 1 (1.6)
Neutropenia 1 (3.2) 1 (3.2) 2 (6.5) 8 (26.8) 2 (6.5) 1 (3.2) 9 (14.5) 3 (4.8) 3 (4.8)
Thrombocytopenia 1 (3.2) – 1 (3.2) 3 (9.7) – – 4 (6.5) – 1 (1.6)
Mucositis 4 (12.9) 1 (3.2) – 2 (6.5) 5 (16.1) – 6 (9.7) 6 (9.7) –
Diarrhea 5 (16.1) 3 (9.7) – 7 (22.5) – 2 (6.5) 12 (19.3) 3 (4.8) 2 (3.2)
Anorexia 10 (24.3) 11 (35.4) 1 (3.2) 7 (22.5) 10 (24.3) 1 (3.2) 17 (27.4) 21 (33.9) 2 (3.2)
Nausea 9 (29.0) 7 (22.5) 1 (3.2) 11 (35.4) 3 (9.7) 2 (6.5) 20 (32.3) 10 (16.1) 3 (4.8)
Vomiting 5 (16.1) 3 (9.7) – 8 (26.8) 3 (9.7) – 13 (21.0) 6 (9.7) –
Abdominal pain 8 (26.8) 5 (16.1) 3 (9.7) 10 (32.3) 9 (29.0) 1 (3.2) 18 (29.0) 14 (22.6) 4 (6.5)
Dyspepsia 8 (26.8) 4 (12.9) – 8 (26.8) 3 (9.7) 1 (3.2) 16 (25.8) 7 (11.3) 1 (1.6)
Weight loss 2 (6.5) 1 (3.2) – 3 (9.7) 3 (9.7) 1 (3.2) 5 (8.1) 4 (6.5) 1 (1.6)
General weakness 6 (19.3) 5 (16.1) – 3 (9.7) 6 (19.4) 1 (3.2) 9 (14.5) 11 (17.8) 1 (1.6)
Skin pigmentation 13 (41.9) 1 (3.2) – 10 (32.3) 2 (6.5) – 23 (37.1) 2 (3.2) –
Skin rash 7 (22.6) 2 (6.5) – 4 (12.9) 4 (12.9) – 11 (17.7) 6 (9.7) –
Itching sensation 4 (12.9) 1 (3.2) – 5 (16.1) 3 (9.7) – 9 (14.5) 4 (6.5) –
Hand–foot syndrome – – – 2 (3.2) – – 2 (3.2) – –
Hematochezia – – 1 (3.2) – 1 (3.2) 1 (3.2) – 1 (1.6) 2 (3.2)
Musculoskeletal pain 6 (19.3) 1 (3.2) 4 (12.9) 3 (9.7) 1 (3.2) 10 (16.1) 4 (6.5) 1 (1.6)
Constipation 6 (19.3) – – 3 (9.7) 4 (12.9) – 9 (14.5) 4 (6.5) –
Serum ALP 11 (35.4) 3 (9.7) – 9 (29.0) 2 (6.5) – 20 (32.3) 5 (8.1) –
Serum AST/ALT 5 (16.1) 1 (3.2) – 2 (6.5) 1 (3.2) 1 (3.2) 7 (11.3) 2 (3.2) 1 (1.6)
Hyperbilirubinemia 4 (12.9) – – 4 (12.9) 3 (9.7) 2 (6.5) 8 (12.9) 3 (4.8) 2 (3.2)
Serum creatinine 1 ( 3.2 ) – – – – – 1 (1.6) – –
Grading according to the National Cancer Institute Common Toxicity Criteria (Version 2.0).
a There were no cases of grade 4 adverse events.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
549Jeung, Rha, Kim et al.
www.TheOncologist.com
Ta
bl
e
5.
Ph
ar
m
ac
ok
in
et
ic
pr
of
ile
D
os
e
(m
g/m
2 )
K
or
ea
(af
ter
28
da
ys
)
U
.S
.
(si
ng
le
do
se
)
Ja
pa
n
(af
ter
28
da
ys
)
C
yc
le
1
C
yc
le
3
35
(n

10
)
35
.9
(n

10
)
35
(n

3)
40
(n

3)
35
(n

3)
40
(n

3)
FT
T m
a
x
(ho
urs
)
1.
8
	
1.
9
1.
8
	
1.
9
4.
0
	
0.
3
1.
3
	
1.
1
1.
8
	
0.
5
3.
0
	
1.
8
C m
a
x
(ng
/m
l)
4,
48
4
	
1,
23
1
5,
48
7
	
4,
07
8
4,
14
3
	
25
7
6,
42
8
	
2,
56
3
1,
94
3
	
36
5
4,
16
6
	
83
4
A
U
C 0
–4
8
(ng
·h/
ml
)
99
,9
07
	
38
,9
99
13
2,
60
6
	
12
,9
91
10
3,
63
4
	
7,
91
8
12
9,
45
5
	
60
,0
26
18
,8
63
	
2,
19
0
80
,0
32
	
20
,9
93
T 1
/2
(ho
urs
)
22
.1
	
5.
1
19
.4
	
10
.3
17
.1
	
0.
3
20
.1
	
6.
7
10
.8
	
1.
7
16
.2
	
2.
4
5-
FU T
m
a
x
(ho
urs
)
3.
3
	
1.
2
2.
7
	
1.
2
4.
0
	
1.
1
2.
0
	
0.
3
2.
5
	
1.
0
3.
4
	
1.
3
C m
a
x
(ng
/m
l)
91
	
23
13
3
	
46
84
	
12
13
9
	
15
17
6
	
22
11
4
	
41
A
U
C 0
–4
8
(ng
·h/
ml
)
75
0
	
12
0
76
7
	
19
4
83
1
	
11
6
91
6
	
27
4
1,
00
4
	
57
60
9
	
17
0
T 1
/2
(ho
urs
)
4.
2
	
1.
2
3.
7
	
1.
6
4.
4
	
0.
9
5.
6
	
1.
3
2.
0
	
0.
2
2.
9
	
1.
1
CD
H
P
T m
a
x
(ho
urs
)
2.
0
	
0.
2
2.
0
	
1.
7
4.
0
	
0.
2
1.
3
	
1.
1
2.
3
	
1.
3
2.
6
	
1.
8
C m
a
x
(ng
/m
l)
19
1
	
14
23
1
	
14
7
34
1
	
14
7
52
4
	
26
9
39
8
	
19
6
27
6
	
14
2
A
U
C 0
–4
8
(ng
·h/
ml
)
1,
35
9
	
37
3
1,
68
3
	
68
7
1,
48
8
	
98
2,
21
6
	
74
0
1,
78
4
	
59
1
1,
36
4
	
35
2
T 1
/2
(ho
urs
)
9.
4
	
4.
9
3.
8
	
0.
8
7.
1
	
4.
0
4.
3
	
2.
9
4.
3
	
0.
3
4.
2
	
1.
4
O
xo T
m
a
x
(ho
urs
)
2.
2
	
1.
8
1.
8
	
1.
9
6.
0
	
2.
8
2.
0
	
0.
4
2.
5
	
1.
0
2.
6
	
2.
1
C m
a
x
(ng
/m
l)
33
.1
	
1.
0
10
5
	
25
24
.1
	
8.
6
84
.4
	
4.
5
43
	
29
13
0
	
19
0
A
U
C 0
–4
8
(ng
·h/
ml
)
33
7
	
80
47
7
	
85
32
8
	
13
7
35
5
	
16
20
6
	
22
9
55
0
	
50
0
T 1
/2
(ho
urs
)
5.
3
	
1.
2
3.
9
	
2.
4
5.
9
	
0.
9
4.
1
	
3.
0
3.
7
5.
0
	
2.
5
U
.S
.d
at
a
ar
e
fro
m
H
of
fP
M
,S
aa
d
ED
,A
jan
iJ
A
et
al
.P
ha
se
Is
tu
dy
w
ith
ph
ar
m
ac
ok
in
et
ic
so
fS
-1
o
n
an
o
ra
ld
ai
ly
sc
he
du
le
fo
r2
8
da
ys
in
pa
tie
nt
sw
ith
so
lid
tu
m
o
rs
.
Cl
in
Ca
nc
er
R
es
20
03
;9
:1
34
–
14
2;
Ja
pa
n
da
ta
w
er
e
o
bt
ai
ne
d
fro
m
H
ira
ta
K
,H
or
ik
os
hi
N
,A
ib
a
K
et
al
.P
ha
rm
ac
ok
in
et
ic
st
ud
y
o
fS
-1
,a
n
o
v
el
o
ra
lf
lu
or
ou
ra
ci
la
n
tit
um
or
dr
ug
.C
lin
Ca
nc
er
R
es
19
99
;5
:2
00
0–
20
05
.
In
th
e
st
ud
y
by
H
ira
ta
et
al
.[
28
],
an
av
er
ag
e
sin
gl
e
do
se
o
f3
5.
9
m
g/
m
2
w
as
gi
ve
n
(ra
ng
e,
31
.7
–3
9.
7
m
g/
m
2 ).
A
bb
re
vi
at
io
ns
:5
-F
U
,5
-fl
uo
ro
ur
ac
il;
A
U
C 0
–
48
,
ar
ea
u
n
de
rt
he
pl
as
m
a
co
n
ce
n
tr
at
io
n-
ve
rs
us
-ti
m
e
cu
rv
e
fro
m
tim
e
0
to
48
ho
ur
s(
las
tm
ea
su
re
d
pl
as
m
a
co
n
ce
n
tr
at
io
n);
CD
H
P,
5-
ch
lo
ro
-2
,4
-d
ih
yd
ro
xy
py
rid
in
e;
C m
a
x
,
m
ax
im
um
pl
as
m
a
co
n
ce
n
tr
at
io
n;
FT
,t
eg
af
ur
;T
1/
2,
el
im
in
at
io
n
ha
lf-
lif
e;
O
xo
,p
ot
as
siu
m
o
x
o
n
at
e;
T m
a
x
,
tim
e
to
m
ax
im
um
pl
as
m
a
co
n
ce
n
tr
at
io
n.
550 S-1 Monotherapy in Advanced Gastric Cancer
S-1 showed remarkably good tolerability in our patients
at the initial dosage. All but two patients completed the
planned schedule, which encouraged us to continue the
study with an escalated dose of 40 mg/m2 bid (80 mg/m2 a
day). Twenty-three patients (74%) in group 2 received S-1
at 140 mg or more. Even with this high dose level, the pa-
tients still showed favorable compliance. The actual dose
intensity of our patients was 367 mg/m2 per week, which is
the highest ever obtained with S-1 monotherapy. These
findings suggest that S-1 is a promising alternative to anti-
metabolites in gastric cancer with very good compliance in
a Korean population.
This high compliance is a result of the favorable safety
profile. It is well known that myelosuppression and diar-
rhea are the events that precluded dose escalation in Japan,
whereas gastrointestinal toxicity and skin reaction were the
limiting factors in western trials [11, 16]. On the other hand,
the major adverse event in our patients was anemia. Thir-
teen percent of patients experienced grade 3 anemia at least
once during their course of treatment, and 42% of the pa-
tients experienced grade 2–3 anemia in the first cycle. Al-
though more grade 2–3 anemia was observed in group 2
patients as the cycle progressed, the overall incidences of
anemia in the entire patient population did not change sig-
nificantly throughout the cycles. We eliminated bleeding
when counting anemia. There have been several reports of
hemolytic anemia associated with 5-FU or uracil-tegafur
(UFT) [29, 30]. Although no specific laboratory test was
conducted to diagnose hemolytic anemia, there was suffi-
cient evidence to exclude its possibility, because clinically
no dark-colored urine, jaundice, or hepatosplenomegaly
were observed. We had five cases of grade 2–3 hyperbiliru-
binemia, but they were not concordant with the cases of
anemia. Moreover, most reports of 5-FU- or UFT-related
hemolytic anemia were associated with long-term exposure
or rechallenge of the drug, which is contrary to our obser-
vation of the early appearance of anemia. Another point of
note is the hyperbilirubinemia that was exclusive to group 2
patients, which reminds us of the DLT in the U.S. phase I
trial [18]. Its mechanism is still unclear, but it may be sug-
gestive of the possibility of saturation of glucuronyltrans-
ferase enzyme activity or hepatobiliary transport of S-1 at
this dose [31, 32].
Even though we found a high compliance rate, our trial
Figure 2. (A): Supervised hierarchical clustering of the selected 18 genes for which copy number changes were associated with
hemoglobin reduction with S-1 treatment. The white block indicates the mild hemoglobin reduction group (MRG, 1.0 Hb/
cycle) and the black block indicates the severe hemoglobin reduction group (SRG, 1.0 Hb/cycle). (B): Receiver operating
characteristic (ROC) curve of prediction logistic regression model.
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showed a lower tumor response rate of 19%, compared with
previous Japanese trials [12–14, 16]. The first point to con-
sider with this discrepancy is whether the gastric mass was
included for response evaluation or not. Most Japanese tri-
als of S-1 have traditionally considered the gastric mass as
measurable disease, but their criteria depend on gastro-
graphic and/or endoscopic findings, which are subjective
and have a risk of bias [12, 14]. The second point is our high
rate of unconfirmed PR (19%). Most of these resulted from
a short response duration, which was not long enough to be
confirmed in next cycle. Moreover, one third of the patients
showed progressive disease with new lesions. This may re-
flect the high tumor burden and biologic heterogeneity of
gastric cancer, leading to the rapid appearance of metastatic
clones even with responding pre-existing lesions [33, 34].
Nevertheless, the efficacy rate of S-1 is comparable with that
of PCI 5-FU (18%–26%) and other oral fluoropyrimidines
such as UFT (10%–28%) and capecitabine (19%–34%),
which reaffirms the efficacy of S-1 in gastric cancer [35–37].
Pharmacokinetic evaluation can offer useful informa-
tion regarding the ethnic influence on treatment outcome.
At an equivalent dose level of 35 mg/m2, the pharmacoki-
netic parameters of 5-FU, FT, and CDHP were similar to
the Japanese findings, rather than those of the U.S. (Table
5) [28]. The dose increase to 40 mg/m2 showed an upward
tendency in the general pharmacokinetic parameters com-
pared with 35 mg/m2, but the AUC of 5-FU increased only
marginally. This suggests that the capacity to convert FT to
5-FU (i.e., cytochrome P4502A6) is saturated at this dose
level. The conversion level would also be similar to that of
the Japanese population considering the interethnic profiles
of cytochrome P4502A6 polymorphism of the two popula-
tions [38]. Nevertheless, this pharmacokinetic study cannot
explain the discrepancy in the typical adverse events ob-
served between our results and the Japanese results. This
may imply that other pharmacodynamic or pharmacoge-
netic factors are involved.
Most anticancer drugs act directly upon hematopoietic
progenitors or indirectly on the bone marrow microenviron-
ment, hematopoiesis regulatory factors [39]. We assumed
that the S-1–induced anemia was related to erythropoiesis
rather than bleeding or hemolysis, based on the following:
(a) the anemia occurred continuously after initial treatment;
(b) there existed interpersonal variability in the velocity of
mean Hb reduction per cycle after S-1 treatment; (c) 6
weeks per cycle is long enough to affect erythropoiesis by
S-1; (d) there was gradual macrocytosis with S-1 treatment
(from 91 to 106 fl of mean corpuscular volume), reflecting
deranged DNA synthesis and mitosis; and (e) the anemia
comprised a unique toxicity profile of the S-1–treated Ko-
rean population in colorectal cancer [40]. Based on these
findings, we tried to find genetic changes that are related to
S-1–induced anemia with pharmacogenomic evaluation.
A pharmacogenomic approach could help to predict the
quantitative and qualitative differences in individual sus-
ceptibility and ethnic differences in treatment outcome. We
performed a pharmacogenomic study with genomic DNA
from peripheral blood mononuclear cells, not with tumoral
DNA from cancer tissues. Even though there are still some
controversies, genomic DNA is considered to have the ge-
netic information of normal tissue rather than tumor DNA
[41]. Thus, we thought that it was more rational to use
genomic DNA to predict the influence of S-1 on normal tis-
sue (toxicity) rather than on tumor tissue (response).
Our primary aim was to discriminate the patient at high
risk for Hb reduction from among the patients receiving
S-1. The point is that it is not an absolute risk estimation but
a relative comparison of the risk between the patients who
showed more rapid Hb reduction and those who did not. For
this purpose, we focused on the patient’s velocity of Hb re-
duction during treatment rather than the nadir value itself as
a marker of personal susceptibility to S-1. We indicated the
velocity as the average slope, which is the difference be-
tween the Hb levels (HbinitialHbnadir) divided by the num-
ber of treatment cycles when the initial anemia occurred.
Thus, 18 genes with copy number changes were identified
and they discriminated between the high and low Hb reduc-
tion groups. Among these, Grb7 was recently reported to
participate in the proliferation and maturation of colony-
forming units–erythroid [42, 43]. Another gene, estrogen
receptor  (ESR2), was also associated with differentiation
of pluripotent hematopoietic cells [44]. However, the clin-
ical importance of genetic classifiers is their potential role
as predictive markers. The multifactorial nature of genetic
heterogeneity in pharmacologic pathways makes it unlikely
that a single marker will accurately detect treatment-related
factors. A more promising and powerful approach is to use
panels of genetic classifiers for predictive information. By
combining clinical and genetic factors, we established a
more robust prediction model with high accuracy (92%),
sensitivity, and specificity (93% and 96%, respectively).
This is the first example, to our knowledge, of using mi-
croarray-based CGH as a pharmacogenomic tool for the
prediction of chemotherapy-related outcome. Of course,
the role of a pharmacogenomic approach to explain inter-
ethnic variability remains speculative at this time. These se-
lected genes could offer an insight for future functional
studies concerning chemotherapy-induced anemia. They
might offer subjects on population studies, such as single
nucleotide polymorphisms, to clarify ethnic differences.
We also believe that this predictive model can be clinically
optimized through prospective validation.
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In conclusion, this phase II trial obtained the highest
dose intensity of S-1 ever reported in gastric cancer. Con-
sidering the efficacy of PCI 5-FU of around 20%, we be-
lieve that S-1 demonstrates acceptable efficacy and
comparable survival with good tolerability. Considering
only a modest improvement in efficacy and an increasing
incidence of hyperbilirubinemia with dose elevation, we
suggest that a dose of 35 mg/m2 bid is optimal when design-
ing future combination chemotherapy in gastric cancer, and
that pharmacogenomics may represent a promising area of
future research for individualized chemotherapy.
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